‘What is the best choice of first-line treatment in men with poor prognosis metastatic castration-resistant prostate cancer (mCRPC)?’ Up until today, this important topic under debate daily practice. Although guidelines advocate use taxanes as first CRPC1Gillessen S. Attard G. Beer T.M. et al.Management patients advanced cancer: report consensus conference 2019.Eur Urol. 2020; 77: 508-547Abstra...

Objectives Nested qualitative studies within clinical trials provide the opportunity to better understand participant experiences of participation and identify areas where improved support is required. The purpose this study describe lived men with advanced prostate cancer participating in TheraP trial; a randomised trial 177 Lu-PSMA-617 compared cabazitaxel chemotherapy. Methods Fifteen were r...